trending Market Intelligence /marketintelligence/en/news-insights/trending/ilz4iawqpx7yefiyml9leg2 content esgSubNav
In This List

Puma Biotechnology breast cancer drug approved in EU

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Puma Biotechnology breast cancer drug approved in EU

Puma Biotechnology Inc. said the European Commission approved its medicine Nerlynx months after the European Medicines Agency recommended that it be used as a treatment for breast cancer.

The medicine, also known as neratinib, is intended for adults with early breast cancer who have undergone surgery to reduce the risk of their disease coming back. Specifically, the medicine is meant for early stage hormone-receptor positive HER2- breast cancer.

SNL Image

Nerlynx is expected to be given for one year following treatment with Roche Holding AG's Herceptin, or trastuzumab.

The approval is backed by the results of a phase 3 clinical trial called ExteNET that showed that a higher number of patients who received Nerlynx did not see their disease return when compared to those that received placebo.

Nerlynx will become commercially available throughout Europe during 2019. The medicine is also approved in the U.S.